Operating Expenses
Acquired in-process research and development
Neurocrine Biosciences Acquired in-process research and development increased by 24.7% to $21.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21100.0%, from $100.00K to $21.20M. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development shows a downward trend with a -36.2% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
High levels indicate an active inorganic growth strategy, while low levels suggest a focus on internal development.
Detailed definition
This metric captures the costs associated with acquiring research and development projects from third parties that have...
Peer comparison
Common in the pharmaceutical and biotech sectors where M&A is a primary strategy for pipeline replenishment.
Metric ID:
lly_acquired_in_process_research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.00M | $0.00 | $100.30M | $0.00 | $0.00 | $0.00 | $0.00 | $143.90M | $0.00 | $0.00 | $0.00 | $6.00M | $2.50M | $1.00M | $3.00M | $100.00K | $0.00 | $300.00K | $17.00M | $21.20M |
| QoQ Change | — | -100.0% | — | -100.0% | — | — | — | — | -100.0% | — | — | — | -58.3% | -60.0% | +200.0% | -96.7% | -100.0% | — | >999% | +24.7% |
| YoY Change | — | — | — | — | -100.0% | — | -100.0% | — | — | — | — | -95.8% | — | — | — | -98.3% | -100.0% | -70.0% | +466.7% | >999% |
Range$0.00 – $143.90M
CAGR+35.5%
Avg YoY Growth>999%
Median YoY Growth-97.1%
Current Streak2 quarters growth
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $100.00K | $0.00 | $300.00K | $17.00M | $21.20M |
| Total | $100.00K | $0.00 | $300.00K | $17.00M | $21.20M |
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's acquired in-process research and development?
- Neurocrine Biosciences (NBIX) reported acquired in-process research and development of $21.20M in Q1 2026.
- How has Neurocrine Biosciences's acquired in-process research and development changed year-over-year?
- Neurocrine Biosciences's acquired in-process research and development increased by 21100.0% year-over-year, from $100.00K to $21.20M.
- What is the long-term trend for Neurocrine Biosciences's acquired in-process research and development?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's acquired in-process research and development has grown at a -36.2% compound annual growth rate (CAGR), from $105.30M to $17.40M.
- What does acquired in-process research and development mean?
- Costs paid to acquire unfinished research projects from other companies.